Skip to main content

Table 3 Laboratory findings in a trial of HDIVC in patients with COVID-19

From: Pilot trial of high-dose vitamin C in critically ill COVID-19 patients

Variable Day Vitamin C (n = 27) Placebo (n = 29) Difference, coefficient (95% CI) P Value
Leukocyte count, 109 1 9.5 ± 5.0 11.6 ± 7.2 − 2.0(− 5.4 to -1.5) 0.26
3 8.6[5.7–11.5] 8.4[7.1–12.2] − 0.4(− 3.5 to 2.7) 0.67
7 10.2 ± 6.7 9.6 ± 5.4 0.6(− 3.0 to 4.1) 0.74
Neutrophil count, 109 1 8.2 ± 4.8 10.2 ± 7.1 − 2.0(− 5.3 to 1.4) 0.24
3 6.2[4.5–10.5] 7.1[5.7–9.9] − 0.5(− 3.5 to 2.5) 0.50
7 8.1 ± 6.5 8.2 ± 5.5 − 0.1(− 3.6 to 3.4) 0.95
Neutrophil ratio, % 1 83.5 ± 9.6 85.8 ± 9.9 − 2.3(− 7.7 to -3.1) 0.39
3 85.7[77.1–91.4] 83.3[75.5–91.8] 4.0(− 6.3 to 14.4) 0.70
7 78.5 ± 15.8 81.7 ± 11.5 − 3.2(− 11.2 to 4.8) 0.42
IL-6 1 22.6[8.9–85.5] 54.7[12.3–145.5] -6.2(-129.7 to 117.3) 0.61
3 113.1[21.8–288.7] 37.2[5.6–85.3] 92.4(− 25.1 to 210.0) 0.07
7 19.4[10.6–29.2] 158.0[15.3–259.6] − 165.8(− 301.7 to − 29.8) 0.04
Lymphocyte count, 109 1 0.6[0.4–1.0] 0.5[0.4–1.0] 0.1(− 0.2 to 0.4) 0.49
3 0.6[0.3–1.0] 0.71[0.5–1.1] − 2.6(− 8.6 to 3.4) 0.50
7 0.8[0.4–1.1] 0.7[0.4–1.0] 1.1(− 0.8 to 3.0) 0.25
Lymphocyte ratio, % 1 9.7 ± 7.0 8.1 ± 7.3 1.6(− 2.3 to 5.6) 0.41
3 10.1 ± 9.2 8.7 ± 4.9 1.4(− 2.7 to 5.4) 0.88
7 13.1 ± 11.3 6.8[5.1–13.4] 3.3(− 2.1 to 8.8) 0.23
PCT, ng/mL 1 0.2[0.1–0.6] 0.2[0.1–0.5] − 9.9(− 29.3 to 9.4) 0.80
3 0.4[0.1–3.2] 0.3[0.1–1.1] − 6.6(− 20.5 to 7.3) 0.84
7 0.3[0.1–14.8] 0.2[0.1–0.7] 13.3(− 17.9 to 44.5) 0.18
CRP, mg/L 1 39.9[3.9–86.9] 56.8[40.2–100.2] − 23.2(− 69.5 to 23.1) 0.19
3 43.5[3.4- 65.7] 66.3[29.8–107.4] − 4.8(− 68.1 to 58.5) 0.28
7 29.5[11.0–110.9] 30.2[2.3–131.7] − 12.6(− 75.3, 50.1) 0.68
Total bilirubin, umol/L 1 8.6[6.8- 15.6] 10.8[7.4–18.3] − 1.5(− 7.3 to 4.4) 0.28
3 8.4[6.7–16.1] 14.9[9.9–25.5] − 9.7(− 18.3 to − 0.6) 0.03
7 8.3[6.5–16.2] 15.3[9.0–27.7] − 4.2(− 15.9 to 7.5) 0.11
Creatinine, umol/L 1 64.2[46.9–85.5] 64.2[52.0 -81.7] 26.4(− 50.9 to 103.7) 0.57
3 60.3[37.7–80.4] 70.35[49.80–100.9] 2.5(− 39.9 to − 44.9) 0.15
7 57.5[40.0–7] 63.50[51.7–104.5] − 12.4(− 45.6 to 20.7) 0.13
BUN, mmol/L 1 7.11[4.48–11.10] 6.50[4.9–9.9] 9.3(− 8.8 to 27.4) 0.84
3 7.6 ± 5.0 8.6[5.1–11.4] − 2.1(-5.2 to − 1.0) 0.11
7 8.5 ± 5.7 7.8[5.1–10.5] − 0.7(− 4.1 to 2.7) 0.48
PT, s 1 13.3[12.4–14.6] 12.9[12.5–13.8] − 0.6(− 2.4 to 1.2) 0.97
3 13.9 ± 3.2 13.3[12.7–15.1] − 0.29(− 2.0 to 1.4) 0.33
7 13.0 ± 2.6 13.1[12.4–14.6] − 0.3(− 1.7 to 1.1) 0.08
  1. Data were expressed as mean ± standard deviation, as median [interquartile range]. Odds ratio with 95% CI were calculated by binary logistic regression for the rest. P values were calculated by logistic regression
  2. SD standard deviation, IQR interquartile range, HR hazard ratio, OR odds ratio, CI confidence interval, HDIVC high-dose intravenous vitamin C, COVID-19 coronavirus disease 2019, SD standard deviation; IQR interquartile range, PCT procalcitonin, CRP C-reactive protein, BUN blood urea nitrogen, PT prothrombin time, IL-6 interleukin-6